Vancomycin for Primary Sclerosing Cholangitis | MicrobiomeTrials← Back to trialsNCT03710122
Vancomycin for Primary Sclerosing Cholangitis
TERMINATEDPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2020-01-23Est. Completion: 2025-03-03
Enrollment target: 102 participants Locations- Mayo Clinic Arizona, Phoenix, Arizona, United States
- Arizona State University, Tempe, Arizona, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
Other microbiome trials you might be interested in
Primary Sclerosing Cholangitis
The purpose of this study is to find out how well and safely elafibranor works compared to placebo in adult participants…
Chandler, United StatesEst. completion Apr 30, 2031
Primary Sclerosing Cholangitis
This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis…
Lancaster, United StatesEst. completion Sep 23, 2031